Literature DB >> 17110085

Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis.

M Ruan1, T Ji, Z Wu, J Zhou, C Zhang.   

Abstract

Midkine, a new member of the heparin-binding growth factor family, was found recently to have a high expression level in many carcinoma specimens, including oesophagus, gall, bladder, pancreas, colorectum, breast and lung carcinomas, but few relevant studies have been performed. The aim of this study was to investigate the expression of midkine in oral squamous cell carcinoma (OSCC) and its correlation with tumour angiogenesis. Surgical specimens from 62 cases of OSCC and 10 cases of normal oral mucosa were examined by immunohistochemistry. The relationship between expression of midkine and the clinicopathological data and tumour angiogenesis was analysed. Midkine proteins were overexpressed in OSCC. The level of midkine expression was found to be significantly correlated with tumour size (P = 0.01), clinical stage (P = 0.002) and prognosis (P = 0.038). High midkine expression was associated with higher tumour angiogenesis as reflected by increased vascular endothelial growth factor expression (P = 0.005) and higher microvessel density (P = 0.004). These results indicate that midkine may be of great value in assessing the development and prognosis of OSCC, and could be taken as a new target for OSCC therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110085     DOI: 10.1016/j.ijom.2006.09.004

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  17 in total

1.  Role of midkine-progranulin interaction during angiogenesis of hepatocellular carcinoma.

Authors:  Huilian Huang; Jing Li; Yongliang Lu; Lishan Min; Dongli Li; Licheng Dai
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Embryological Origin of Human Smooth Muscle Cells Influences Their Ability to Support Endothelial Network Formation.

Authors:  Johannes Bargehr; Lucinda Low; Christine Cheung; William G Bernard; Dharini Iyer; Martin R Bennett; Laure Gambardella; Sanjay Sinha
Journal:  Stem Cells Transl Med       Date:  2016-05-18       Impact factor: 6.940

Review 4.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

5.  Over-expressed and truncated midkines promote proliferation of BGC823 cells in vitro and tumor growth in vivo.

Authors:  Qing-Ling Wang; Hui Wang; Shu-Li Zhao; Ya-Hong Huang; Ya-Yi Hou
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

6.  Midkine mRNA is overexpressed in pancreatic cancer.

Authors:  Seiji Ohhashi; Kenoki Ohuchida; Kazuhiro Mizumoto; Takuya Egami; Jun Yu; Lin Cui; Hiroki Toma; Shunichi Takahata; Toshinaga Nabae; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

7.  The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

Authors:  Edward Htun van der Horst; Brendon T Frank; Lawrence Chinn; Angela Coxon; Shyun Li; Fanny Polesso; Anthony Slavin; Astrid Ruefli-Brasse; Holger Wesche
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

Review 8.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 9.  Midkine in inflammation.

Authors:  Ludwig T Weckbach; Takashi Muramatsu; Barbara Walzog
Journal:  ScientificWorldJournal       Date:  2011-12-27

Review 10.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.